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Prevention of skipping of exon 7 during pre-mRNA splicing of Survival Motor Neuron 2 (SMN2) holds the
promise for cure of spinal muscular atrophy (SMA), a leading genetic cause of infant mortality. Here, we report
T-cell-restricted intracellular antigen 1 (TIA1) and TIA1-related (TIAR) proteins as intron-associated positive
regulators of SMN2 exon 7 splicing. We show that TIA1/TIAR stimulate exon recognition in an entirely novel
context in which intronic U-rich motifs are separated from the 5 splice site by overlapping inhibitory elements.
TIA1 and TIAR are modular proteins with three N-terminal RNA recognition motifs (RRMs) and a C-terminal
glutamine-rich (Q-rich) domain. Our results reveal that any one RRM in combination with a Q domain is
necessary and sufficient for TIA1-associated regulation of SMN2 exon 7 splicing in vivo. We also show that
increased expression of TIA1 counteracts the inhibitory effect of polypyrimidine tract binding protein, a
ubiquitously expressed factor recently implicated in regulation of SMN exon 7 splicing. Our findings expand
the scope of TIA1/TIAR in genome-wide regulation of alternative splicing under normal and pathological
conditions.
Current estimates suggest that 95 to 100% of human genes
with two or more exons are alternatively spliced, affecting all
major aspects of cellular metabolism under normal and patho-
logical conditions (12, 42). The mechanism of alternative splic-
ing involves a complex combinatorial control in which exonic
and intronic splicing enhancers (ESEs and ISEs, respectively),
and silencers (ESSs and ISSs, respectively) play significant
roles. In general, serine- and arginine-rich (SR) proteins pro-
mote exon inclusion through interactions with ESEs, whereas
heteronuclear ribonucleoproteins (hnRNPs) promote exon ex-
clusion through interactions with ESSs and ISSs (13, 34). Most
of these proteins contain at least one RNA recognition motif
(RRM) that is responsible for providing target specificity (11).
Depending on the site of binding, SR proteins can also pro-
mote exon skipping, and hnRNPs can promote exon inclusion
(17, 26). Alternative splicing is also regulated by several other
factors not related to SR proteins and hnRNPs. In addition,
RNA structures that directly or indirectly affect spliceosome
assembly and catalytic core formation could modulate the out-
come of splicing (42, 47).
The splicing reaction calls for the highest degree of precision
since a shift in splicing position by 1 nucleotide could have
devastating consequences (12). The biggest challenge in our
understanding of alternative splicing emanates from our inabil-
ity to fully comprehend the combinatorial control exerted by
cis elements. Using functional or genomic approaches, a vast
majority of studies have concentrated on deciphering the na-
ture of cis elements located within exons (6, 27, 61, 63, 66).
Very few studies have been dedicated to intronic cis elements,
mostly focusing on the regions that flank exonic sequences (59,
65, 66, 69). Recent genome-wide analyses of intronic sequences
revealed significant enrichment of U-rich motifs downstream of
5 splice sites (3, 19). Furthermore, depletion of T-cell-re-
stricted intracellular antigen 1 (TIA1) protein and TIA1-like 1
(TIAL1; also referred to as TIAR) protein has been found to
promote exon skipping in genes containing U-rich stretches
immediately downstream of the 5 splice site (ss) particularly
between 6 and 30 the intron positions (3). These findings
are consistent with an earlier report in which TIA1 and TIAR
showed preference for certain types of U-rich motifs in vitro
(16). TIA1 is a modular protein which contains three RRMs at
the N terminus and an auxiliary glutamine rich (Q-rich) do-
main at the C terminus (29, 57). Based on in vitro studies, it has
been proposed that TIA1 recruits U1 snRNP through direct
interactions with the U1 snRNP and U-rich intronic sequences
adjacent to the 5 ss (18). There is another study that suggested
but did not conclusively prove that TIA1 may also be active
from a greater distance from the 5 ss (71). An earlier finding
that Saccharomyces cerevisiae TIA1 homologue NAM8 is able
to activate the 5 ss from a longer distance may argue for a
general role of TIA1 in splicing regulation in higher eukaryotes
(67). Currently, it is not known if TIA1 could stimulate exon
inclusion through binding to U-rich intronic sequences away
from the 5 ss in an altered context in which intronic sequences
adjacent to the 5 ss are known to be negative splicing regula-
tors. In addition to the role of TIA1 in pre-mRNA splicing in
the nucleus, another well-known TIA1 function pertains to
stress granule formation and translation repression in the cy-
toplasm (1, 20). However, the mechanisms by which different
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TIA1 domains participate in critical in vivo events such as
nucleo-cytoplasmic shuttling and protein-protein and protein-
RNA interactions remain poorly understood.
Spinal muscular atrophy (SMA), the second most common
autosomal recessive disorder, is caused by deletions or muta-
tions of the Survival Motor Neuron 1 (SMN1) gene (36). A
nearly identical copy of the gene, SMN2, fails to compensate
for the loss of SMN1 because exon 7 is skipped, producing the
truncated protein SMN7, which is unstable (8, 31, 58). SMN1
and SMN2 differ by a critical C-to-T substitution at position 6
(C6U transition) of exon 7 in SMN2. C6U is sufficient to trigger
exon 7 skipping due to a loss of an ESE associated with SF2/
ASF and/or a gain of a silencer associated with hnRNP A1 (38,
44). Skipping of SMN2 exon 7 is facilitated by a number of
inhibitory elements clustered around the 5 ss of exon 7. These
include TSL2 (an inhibitory RNA structure sequestering the 5
ss of exon 7), a 3 cluster (an ESS), and intronic splicing
silencer N1 (ISS-N1) that harbors two hnRNP A1 motifs (24,
48, 50, 51). ISS-N1 partially overlaps an 8-nucleotide-long GC-
rich motif, which exerts its own inhibitory effect (52). Due to
the direct significance for a major genetic disease, splicing of
SMN exon 7 has become one of the most studied systems in
humans. Consistently, several factors including Tra2-1, SF2/
ASF, hnRNP A1, hnRNP G, SRp30c, hnRNP Q1, and Sam68
have been shown to modulate SMN exon 7 splicing (7, 44, 56).
Most of these factors interact directly or indirectly with se-
quences of exon 7. Recently, polypyrimidine tract binding pro-
tein (PTB) and far-upstream element (FUSE) binding protein
have been shown to interact with element 1, a previously de-
scribed inhibitory element within intron 6 of SMN (4). Two
independent studies have resulted in the identification of ISEs
within intron 7 (21, 41). However, factors interacting with these
ISEs remain unknown. SMN exon 7 is flanked by an 6-kb-long
intron 6 and 444-base-long intron 7. Currently, there is no
report of a splicing factor that promotes SMN2 exon 7 inclu-
sion by binding to an intronic sequence.
Here, we report TIA1 as a positive regulator of SMN2 exon
7 splicing. It promotes exon 7 inclusion by binding to U-rich
intronic motifs presented in a novel context where these motifs
are separated from the 5 ss by the strong inhibitory element
ISS-N1. Our results expand the scope of splicing regulation by
TIA1 and TIAR through a unique combinatorial control in
which strict requirement of U-rich motifs adjacent to the 5 ss
is obviated. Using purified protein, we show that the affinity of
two adjacent U-rich motifs within SMN2 intron 7 is better than
one of the best TIA1 binding sequences isolated by in vitro
selection (16). We also demonstrate that the Q-rich domain in
combination with any one of the three RRMs is necessary and
sufficient for the stimulatory effect of TIA1 in vivo. Further, we
show that the stimulatory effect of TIA1 offsets the inhibitory
effect of PTB. This study constitutes the first report of SMN
exon 7 splicing regulation by a Q-rich-domain-containing pro-
tein and brings a new perspective to splicing regulation of a
critical housekeeping gene associated with a major genetic
disease of children and infants.
MATERIALS AND METHODS
Plasmid constructs. Several of the minigene splicing cassettes and plasmids
here have been described previously: pSMN1I6 and pSMN2I6 (49),
SMN2ISS-N1, ISS-N1/M35, Casp3Avr and Casp3ISS-N1 (48), pTBEx12-50A
(43), pTBApo-ISE3m (40), myc-PTB (62), SMN2I7190–406, and Casp3SMN2
(53). In this study we refer to pSMN1I6 and pSMN2I6 as SMN1 and SMN2.
Generation of other clones has been described in the supplemental material. All
primers were obtained from Integrated DNA Technologies (Coralville, IA).
Deletions and site-specific mutations in the minigenes of interest were intro-
duced by a strategy described earlier (48). A Casp3-exon7-ISS-N1 minigene was
generated by replacing Casp3 exon 6 with SMN2 exon 7 and simultaneously
inserting the ISS-N1 sequence 9 nucleotides downstream.
Human 3XFLAG-hTIA1 mammalian expression vector was generated as fol-
lows. Three copies of the FLAG tag (3XFLAG) sequence 5-ATG GAC TAC
AAA GAC CAT GAC GGT GAT TAT AAA GAT CAT GAC ATC GAC TAC
AAA GAC GAC GAT GAC AAG ACG CGT TCT AGA-3 (the downstream
Mlu site is shown in italics and the XbaI site is underlined) were added (in frame)
to the 5 end of human TIA1 cDNA during a two-step PCR. PCR was performed
using Phusion High-Fidelity DNA polymerase (New England BioLabs, Ipswich,
MA) and human cDNA prepared from HeLa cells. The amplified sequence
(3XFLAG tag followed by in-frame TIA1 cDNA sequence) was then cloned in
the EcoRI-SalI restriction sites of a pCI-neo mammalian expression vector
(Promega, Madison, WI). To distinguish between the full-length TIA1 and
TIA15, Escherichia coli colonies were screened by PCR using Taq DNA poly-
merase (Invitrogen, Carlsbad, CA) and the primer pair 5hTIA1 (5-GCC CAA
GAC TCT ATA CGT CGG TAA CC-3) and 3hTIA1 (5-GGT GCA AAA
GCA GCT TTT ATA TCT TC-3). The 3XFLAG-hTIA1 plasmid digested with
Mlu and SalI was subsequently used for cloning of different TIA1 domains as
well as TIAR and TIAR3. Different domains of TIA1 were generated by PCR
using 3XFLAG-hTIA1 as a template. The regions of the wild-type full-length
TIA1 included in each 3XFLAG domain construct were the following: RRM1,
amino acids (aa) 2 to 110; RRM2, aa 93 to 197; RRM3, aa 185 to 289 followed
by 13 additional unrelated amino acids; Q, aa 260 to 386; RRM1Q, aa 2 to 92
plus aa 273 to 386; RRM2Q, aa 93 to 197 plus aa 272 to 386; RRM3Q, aa 199
to 386; RRM12, aa 2 to 193 followed by 10 additional unrelated amino acids;
RRM13, aa 2 to 92 plus aa 198 to 283; RRM23, aa 82 to 299; RRM1, aa 82
to 386; RRM2, aa 2 to 92 plus aa 198 to 386; RRM3, aa 2 to 198 plus aa 278
to 386; RRM123, aa 2 to 299; TIA1Q1, aa 2 to 367; TIA1Q2, aa 2 to 349;
TIA1Q3, aa 2 to 329; TIA1Q4, aa 2 to 309; TIA1Q5b, aa 2 to 283; TIA1-
3Q, aa 2 to 293 plus 344 to 386; fusion 1a, aa 2 to 299 followed by 32 unrelated
amino acids, and fusion 2b, aa 2 to 299 followed by a glutamine-rich segment of
33 unrelated amino acids. TIAR and TIAR3 sequences were amplified by
reverse transcription-PCR (RT-PCR) using total RNA prepared from HeLa
cells and the primer pair 5MluhTIAR (5-ACC AAG ACG CGT TCT AGA
ATG GAA GAC GAC GGG CAG CCC CGG-3) and 3SalhTIAR (5-CAT
ATA TAT GTC GAC TCA CTG TGT TTG GTA ACT TGC CAT AC-3) (Mlu
and SalI sites are shown in italics). To distinguish between the full-length TIAR
and TIAR3, E. coli colonies were screened using PCR with Taq DNA poly-
merase and the primer pair 5hTIAR (5-CAG AAG TCC TTA TAC TTC AGT
TG-3) and 3hTIAR (5-CTA ATG CAG CAG CTG CAT CTC TG-3). All
constructs were sequenced before their use. According to sequencing results, the
generated 3XFLAG-hTIA1 construct has a silent mutation (GGC to GGT) at
amino acid position 307.
Templates for T7 in vitro transcription were generated as follows. SMN2 intron
7 sequences, wild type as well as those containing deletions/site-specific substi-
tutions, were amplified from the corresponding SMN2 minigenes using Phusion
High-Fidelity DNA Polymerase and the following primer combinations: P167
(5-GTA TGG TAC CTA ATA CGA CTC ACT ATA GGG TAA GTC TGC
CAG CAT TAT GAA AG-3) and P164 (5-GCA TAA GCT TTT TAA ATG
TTC AAA AAC ATT TG-3) for wild type (WT), T7 with a deletion of residues
29 to 60 (T729-60), T725-34, T729-40, T737-48, T746-55, T750-60,
T753-64, T7-URC2S3A (where URC2S3A is U-rich cluster 2 with substitutions
for three U residues), T7-URC2S3B (where B indicates a substitution of three
difference U residues in URC2), T7-URC2S6A, T7-URC2S4A, T7-URC1S2A,
T7-URC1S4A, and T7-URC1S6A constructs; P167 and P165 (5-GCA TAA
GCT TTT TAA ACC ATA AAG TTT TAC AAA-3) for the T756-82 con-
struct; P167 and P166 (5-GCA TAA GCT TTT TCA TTT GTT TTC CAC AAA
CC-3) for the T770-82 construct; and P167 and P61-74 (5-GCA TAA GCT
TTT TAA ATG TTC TCC ACA AAC CA-3) for T761-74 construct. In the
above primers, T7 promoter sequence is underlined and KpnI/HindIII re-
striction sites are shown in italics. The generated PCR fragments were di-
gested with KpnI and HindIII and cloned into the pUC19 vector. As a
positive control in our filter binding assay, we used “sequence 1-1” reported
to be a high-affinity TIA1 binder (16). The DNA template for RNA sequence
1-1 was generated by PCR using primers P187 (5-GTA TGG TAC CTA ATA
CGA CTC ACT ATA GGG TCT TTT TAA GTC GTA CCT AAT CC-3)
and P163 (5-GCA TAA GCT TGG CCG TTC GAC GAG TAT ACA TCC
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TAC-3) and the oligonucleotide TEMP (5-TTT AAG TCG TAC CTA ATC
CTC GTC TCA GTG CCA TAG TGT AGG ATG TAT ACT CGT CGA
AC-3) as a template. In the above primers, T7 promoter sequence is under-
lined, and KpnI/HindIII sequences are shown in italics. A PCR fragment
digested with KpnI and HindIII was cloned in the pUC19 vector. All plasmids
were sequenced before their use.
Cell culture, siRNA, and ASOs. Unless otherwise stated, all tissue culture
media and supplies were purchased from Invitrogen. HeLa cells were obtained
from the American Type Culture Collection and were cultured in Dulbecco’s
modified Eagle’s medium (DMEM) supplemented with 10% fetal bovine serum
(FBS). Primary fibroblasts from an SMA type I patient (repository number
GM03813) were obtained from Coriell Cell Repositories (Camden, NJ). These
cells were grown in minimal essential medium (MEM) supplemented with 2 mM
GlutaMAX-I and 10% FBS. Wild-type mouse embryonic fibroblasts (MEF) and
TIA/ cells were a kind gift from Paul Anderson (33). These cells were
maintained in DMEM supplemented with 10% FBS. Small interfering RNAs
([siRNAs] custom or ON-TARGETplus SMARTpool) against the proteins of in-
terest and antisense oligonucleotides (ASOs) used in this study were purchased
from Dharmacon Inc. (Lafayette, CO). An ON-TARGETplus nontargeting pool
was used as a negative siRNA control. A custom siRNA duplex targeting region
from position 1022 to position 1044 was used to knock down TIAR. The ASOs
incorporated 2-O-methyl modification and phosphorothioate backbone as de-
scribed earlier (48).
Cell transfections. Unless stated otherwise, cotransfections of cells with a
protein expression vector, minigene of interest, and/or ASOs were performed
using Fugene HD (Roche Applied Science, Indianapolis, IN) following the
manufacturer’s recommendations. Briefly, depending on the amount of HeLa
cells needed for analysis, 16 h before transfection they were plated in either a
24-well plate or 6-well plate at a density of 0.9  105 cells per well or 4.8  105
cells per well, respectively. The amounts of minigene DNA, protein expression
vector, and ASO used are indicated in the figure legends. In each experiment the
ratio between nucleic acids and Fugene HD was maintained at 1:3.5. Cells were
collected 24 h after transfection. For total RNA preparation only, cells trans-
fected in 24-well plates were washed with phosphate-buffered saline (PBS; In-
vitrogen) and lysed in Trizol reagent (Invitrogen) directly in each well. For
simultaneous protein and RNA analysis, HeLa cells were transfected in six-well
plates, washed with ice-cold PBS three times 24 h later, and collected by scraping.
One-fourth of the cells were used for total RNA isolation, and the rest were used
for making whole-cell extracts. If transfected cells were also needed for immu-
nofluorescence (IF), we performed transfection of cells in 60-mm dishes (1.1 
106 cells were plated per dish). At 6 to 8 h after transfection, cells were
trypsinized, 1/12 of them were replated in 24-well plates containing glass cover-
slips to be used for IF, 1/4 were plated in six-well plates to be collected for total
RNA preparation, and the rest of the cells were returned to 60-mm dishes to be
collected for making whole-cell extracts as described above. For cytoplasmic and
nuclear protein fractionation, HeLa cells were preplated in 100-mm dishes at a
density of 3  106 cells per dish followed by transfection with 3XFLAG-hTIA1
plasmid 16 h later. Cells were collected for fractionation and total RNA
preparation 24 h after transfection. For RNA interference (RNAi), HeLa cells
were transfected using Lipofectamine 2000 (Invitrogen). Here, the number of
cells plated before transfection was increased to 5.5  105 cells per well of a
six-well plate. Eight hours after transfection, cells in each well were trypsinized
and divided among three wells for sample collection at 24 (total RNA), 48 (total
RNA and protein), and 72 (total RNA) hours posttransfection. Transfection of
MEF and TIA/ cells with SMN1/SMN2 minigenes was done using Lipo-
fectamine 2000. These cells were plated at a density of 2.8  105 cells per well
16 h prior to transfection. Lipofectamine 2000 was also used to transfect SMA
patient fibroblasts GM03813 (plated at 1.5  105 cells per well) with ASOs.
RT-PCR analysis. Total RNA was isolated using Trizol reagent following the
manufacturer’s recommendations. To generate cDNA, reverse transcription was
carried out using a SuperScript III reaction kit (Invitrogen). An oligo(dT) (In-
vitrogen) was used for pCI-based minigenes, while random hexamers (Invitro-
gen) were used for pTB vector-based minigenes. Generally, 0.8 to 3 g of total
RNA was used per 20 l of RT reaction mixture. Minigene-specific spliced
products were amplified using Taq DNA polymerase and the following primer
combinations: P1 and P2 for SMN minigenes; alfa-23 and BRA2 for pTBXx9-
V456F, pTBEx12-50A, and pTBApo-ISE3m minigenes; and P1 and P55 for
Casp3 minigenes (48). For PCR amplification of endogenous genes, we used the
following pairs of primers: either N-24 and P2 (48) or P31 (5-CAT GAG TGG
CTA TCA TAC TG-3) and P25 (5-CTC GAA GCG GCC GCA GCT CAT
AAA ATT ACC A-3) for human SMN exon 7 and 5Ex6-MoSmn (5-CTG TCT
GGA TGA CAC TGA TGC CC-3) and 3Ex8-MoSmn (5-ACC CCA TCT
CCT GAG ACA GAG C-3) for mouse Smn exon 7. When cells were transfected
with the SMN2 minigene, PCR amplification of endogenous human SMN was
performed using the primer combination N-23 (5-CAC CGC CAC CAC CAC
CAC CCC ACT TA-3) and P25 or N-24 and P26 (5-GTA CAA TGA ACA
GCC ATG TC 3). PCRs were performed in the presence of a trace amount of
[	-32P]dATP (3,000 Ci/mmole; Perkin-Elmer Life Sciences, Oak Brook, IL). To
distinguish spliced transcripts of SMN2 from SMN1, the PCR products were
subjected to digestion with DdeI (35). Analysis and quantifications of spliced
products were performed using a FPL-5000 Image Reader and Multi Gauge
software (Fuji Photo Film Inc., Valhalla, NY). Results were confirmed by at least
three independent experiments.
Western blot analysis. Whole-cell extracts from HeLa cells were prepared
using ice-cold radioimmunoprecipitation assay (RIPA) buffer (Boston BioProd-
ucts, Ashland, MA) supplemented with protease inhibitor cocktail (Roche Ap-
plied Science). Fractionations of cytoplasmic and nuclear proteins from HeLa
cells and mouse embryonic fibroblasts were performed using an NE-PER Nu-
clear and Cytoplasmic Extraction kit (Pierce, Rockford, IL) following the man-
ufacturer’s instructions. The extraction reagents from the kit were supplemented
with Halt protease inhibitor single-use cocktail (Thermo Scientific, Waltham,
MA). Protein concentrations were determined using a bicinchoninic (BCA)
protein assay kit (Thermo Scientific). Protein samples were resolved on an 11%
SDS-polyacrylamide gel and transferred on polyvinylidene difluoride (Bio Trace
PVDF) membrane (Pall Life Sciences, Ann Arbor, MI). The following primary
and secondary antibodies were used: mouse monoclonal anti-FLAG M2 (Sigma-
Aldrich, St. Louis, MO), mouse monoclonal anti-hnRNP Q (Sigma-Aldrich),
mouse monoclonal anti-	-tubulin (Sigma-Aldrich), mouse monoclonal anti--
actin (Sigma-Aldrich), rabbit polyclonal anti-Tra2 (Abcam Inc., Cambridge, MA),
rabbit polyclonal to Myc tag (Abcam), rabbit polyclonal to histone H3 (Abcam),
mouse monoclonal to glyceraldehyde-3-phosphate dehydrogenase (GAPDH; Ab-
cam), mouse monoclonal to PTB1 (Abcam), mouse monoclonal to TATA bind-
ing protein (TBP; Abcam), goat polyclonal anti-TIA1 C-20 (Santa Cruz Biotech-
nology, Inc., Santa Cruz, CA), goat polyclonal anti-TIAR C-18 (Santa Cruz
Biotechnology, Inc.), and horseradish peroxidase-conjugated secondary antibod-
ies against mouse (Sigma-Aldrich), rabbit (Jackson ImmunoResearch, West
Grove, PA), and goat (Santa Cruz Biotechnology, Inc.). In most cases, mem-
branes were stripped (10 to 15 min at room temperature) using Restore Western
Blot Stripping Buffer (Thermo Scientific) and reprobed. Immunoreactive pro-
teins were visualized with SuperSignal West Dura Extended Duration Substrate
(Pierce) or SuperSignal West Femto Maximum Sensitivity Substrate (Pierce).
The membranes were scanned using a UVP BioSpectrum AC Imaging System
(UVP, Upland, CA). Results were confirmed by at least three independent
experiments.
In vitro binding assay. Radiolabeled RNA probes used for the nitrocellulose
filter binding assay were generated by in vitro transcription using HindIII-linear-
ized plasmids and a MEGAshortscript T7 kit (Ambion) in the presence of
[	-32P]UTP (3,000 Ci/mmole; Perkin-Elmer Life Sciences). Sequence 1-1 was
the same RNA as described by Dember et al. (16). Transcribed RNA probes
were purified on a denaturing 6% polyacrylamide gel using the crush and soak
method (48) and recovered by ethanol precipitation. Binding was performed
similarly according to the method of Singh et al. (55). Briefly, a 100-l reaction
mixture in binding buffer (40 mM Tris-HCl, pH 7.5 containing 100 mM NaCl, 5
mM MgCl2, 5 mM dithiothreitol [DTT], and 4% glycerol) containing 35 nM
control RNA (either wild type or sequence 1-1), 70 nM mutant RNA, and 1 M
purified TIA1 was incubated for 20 min at room temperature. To capture pro-
tein-bound RNA, the reaction mixture was passed through a nitrocellulose mem-
brane (Protran BA 85; Whatman Inc., Piscataway, NJ). The membrane was
washed once with 800 l of binding buffer followed by washing with high-salt
buffer (binding buffer containing 450 mM NaCl). RNA bound to the membrane
was eluted by phenol-chloroform extraction (150 l of Tris-EDTA [TE] buffer
plus 600 l of phenol-chloroform), followed by ethanol precipitation in the
presence of glycogen (Roche Applied Science), and analyzed on a denaturing 8%
polyacrylamide gel, which was dried and quantified using a FPL-5000 Image
Reader and Multi Gauge software (Fuji Photo Film Inc.). The binding affinity of
a given mutant was compared with wild-type RNA using the following equation:
[amount of boundRNA1/(amount of boundRNA1  amount of boundRNA2)]/
[amount of inputRNA1/(amount of inputRNA1  amount of inputRNA2)], where
RNA1 is a mutant RNA and RNA2 is a control (wild type or sequence 1-1). The
affinity of the mutant RNA compared to that of sequence 1-1 was corrected to
the wild-type level using the following equation: affinityRNA1/affinityWT, where
both affinities were determined by comparing binding reactions with sequence
1-1 as control.
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FIG. 1. Effect of TIA1 on SMN exon 7 splicing. (A) Schematic diagram of the SMN gene. Exons are shown as gray boxes and introns are shown
as broken lines. Sizes of exons and introns are indicated. Locations of the start and stop codons as well as the SMN2-specific DdeI restriction site
are indicated by bold vertical arrows. The annealing positions of primers used for amplifications of endogenous SMN transcripts are shown by
horizontal arrows. (B) In vivo splicing pattern of the SMN2 minigene in the presence of different nuclear proteins from the TIA1 family. A
schematic diagram of the SMN minigenes is shown in the left panel. SMN exons are represented by gray boxes, and intervening introns are shown
by broken lines. Sizes of exons and introns are indicated. Of note, intron 6 has been shortened to improve transfection efficiency (49). Annealing
positions of primers for amplification of minigene-derived transcripts are shown. Results of in vivo splicing of the SMN2 minigene are shown in
the right panel. Data were generated employing HeLa cells grown in 24-well plates. Cells were cotransfected with 0.04 g of SMN2 and 0.46 g
of a 3XFLAG protein expression vector. Total RNA for the splicing assay was prepared from cells harvested 24 h posttransfection. Exon 7-included
() and exon 7-skipped () spliced products are indicated. Results were analyzed as described previously (49). (C) In vivo splicing pattern of
different minigenes in the presence of the overexpressed human full-length TIA1. HeLa cells plated in 24-well plates were cotransfected with 0.04
g of a given minigene and 0.46 g of either pCI-neo (empty vector) or 3XFLAG-hTIA1, and total RNA was prepared 24 h later. In every lane,
upper and lower bands represent exon-included and exon-skipped products, respectively. In CFTR, ApoA-II, Casp3Avr, and Casp3ISS-N1, the
major bands represent the exon-included products while in Casp3-ex7-ISS-N1 the single band represents an exon-skipped product. Numbers on the
left and right are sizes in base pairs. The percentage of exon skipping was calculated from the total value of exon-skipped and exon-included
products. (D) Effect of TIA1 overexpression on endogenous SMN exon 7 splicing. HeLa cells plated in 100-mm dishes were transfected with
increasing amounts of 3XFLAG-hTIA1 plasmid (2.0, 4.5, 9.0, and 18 g). After 24 h cells were collected for total RNA preparation/protein
fractionation. Splicing patterns of endogenous SMN1 and SMN2 are shown in the left panel. Spliced products were analyzed by RT-PCR using
primers located in exon 6 (N-24 in panel A) and exon 8 (P25 in panel A). Following RT-PCR, DdeI digestion was performed to distinguish spliced
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RESULTS
TIA1 restores SMN2 exon 7 inclusion. As the first step to-
ward evaluating the role of a Q-rich-domain-containing RNA
binding protein on SMN2 exon 7 splicing, we cotransfected
HeLa cells with SMN2 minigene and a mammalian expres-
sion vector harboring the complete coding sequence of hu-
man TIA1 or its near homologue TIAR. For the sake of
clarity, diagrammatic representations of the SMN genes and
minigenes have been given in Fig. 1A and B. Of note, exon 8
of SMN2 contains a DdeI restriction site, which is absent in
SMN1. Hence, RT-PCR followed by restriction digestion with
DdeI distinguishes SMN2 and SMN1 transcripts (35) (Fig. 1D).
Our initial screening was performed under nonlimiting con-
centrations of the expressed TIA1/TIAR by using a low mini-
gene-to-expression vector ratio (Fig. 1B). Unless mentioned
otherwise, all expressed proteins carried a 3XFLAG tag, and
their expression levels were monitored by Western blotting
employing antibodies against FLAG. Total RNA was prepared
from cells harvested 24 h posttransfection, and the effect on
SMN2 exon 7 splicing was determined by RT-PCR. As shown
in Fig. 1B, both TIA1 and TIAR were found to restore SMN2
exon 7 inclusion. We next performed experiments with TIA15
and TIAR3, the predominant spliced variants of TIA1 and
TIAR, respectively. These spliced variants are differentially
regulated in different tissue types (28). Similar to their full-
length counterparts, TIA15 and TIAR3 were able to effec-
tively restore SMN2 exon 7 inclusion (Fig. 1B). These results
are consistent with the findings of our subsequent experiments
in which much shorter variants of TIA1 were able to fully
restore SMN2 exon 7 inclusion (described below).
From here on we chose to focus on TIA1 and its potential
role in the regulation of alternative splicing of SMN2 exon 7.
To confirm that the observed stimulatory effect of TIA1 is not
due to a nonspecific response on general splicing, we examined
in vivo splicing patterns of several additional minigenes in the
presence of the overexpressed TIA1. Minigenes chosen for this
experiment represented a variety of splicing cassettes that had
full or partial exon inclusion or skipping properties. Our
results revealed high target specificity in which TIA1 had no
effect on splicing in any of the minigenes tested except
SMN2 (Fig. 1C). Noticeably, the overexpression of TIA1
produced no stimulatory effect on splicing of a hybrid mini-
gene (Fig. 1C, Casp3-exon7-ISS-N1), in which Casp3 exon 6
was exchanged with SMN2 exon 7 and ISS-N1 was added 9
nucleotides downstream. These results indicate that TIA1-
responsive motif(s) involved in stimulation of SMN2 exon 7
inclusion is located outside this exon.
Next, we wished to test the effect of TIA1 on splicing of exon
7 of endogenous SMN2. For this, we transfected HeLa cells
with increasing concentrations of the 3XFLAG-hTIA1 plasmid
(Fig. 1D). Western blotting validated the expression of FLAG-
tagged protein in the nuclear extract (Fig. 1D). Of note, ex-
pressed 3XFLAG-hTIA1 was distinguishable from endoge-
nous TIA1 due to a difference in size. Endogenous SMN2
transcripts were amplified by RT-PCR employing a unique
primer combination followed by DdeI digestion. Even with the
2-fold increase in expression of 3XFLAG-hTIA1 over endog-
enous TIA1, a decrease in SMN2 exon 7 skipping was noticed
(Fig. 1D). With approximately a 10-fold increase in 3XFLAG-
hTIA1 expression, more than a 30% decrease in SMN2 exon 7
skipping was recorded.
Increased SMN exon 7 skipping in TIA1 knockout cells. To
further validate the role of TIA1 on SMN exon 7 splicing, we
took advantage of an embryonic fibroblast cell line derived
from TIA1 knockout mice (TIA1/) (33). Nuclear extract
from TIA1/ cells confirmed complete depletion of TIA1 and
slightly elevated levels of TIAR (Fig. 2A). Amplification of
endogenous mouse Smn transcripts did not show exon 7 skip-
ping in either cell line (Fig. 2B). When wild-type and TIA1/
cells were transfected with the SMN1 or SMN2 minigene, we
observed a
10% increase in SMN1 and SMN2 exon 7 skipping
in TIA1/ cells (Fig. 2C). Given the multitude of stimulatory
splicing factors responsible for SMN exon 7 inclusion, a repro-
ducible decrease of 
10% in exon 7 inclusion in TIA1/ cells
is significant. This finding supports the idea that TIA1 is in-
volved in regulation of exon 7 splicing, and the loss of this
protein cannot be fully compensated by other splicing factors
with redundant functions. The interesting observation that de-
pletion of TIA1 was found to have no adverse effect on splicing
of Smn exon 7 suggests that a TIA1-responsive motif involved
in promotion of SMN exon 7 inclusion might be specific to
humans. There are substantial differences between human and
mouse introns that flank exon 7 (Fig. 2D). For instance, mouse
intron 6 is about half the size of human intron 6, whereas
mouse intron 7 is more than three times larger than human
intron 7. Further, we have recently shown that a C residue
at the 10th intronic position (10C) of SMN intron 7 forms a
long-distance negative interaction with the downstream in-
tronic sequences. The 10C-mediated long-distance interaction
is very specific to position as well as residue and appears to be
absent in the mouse (53). There are additional differences
between human and mouse sequences immediately down-
stream of the 5 ss of exon 7 (Fig. 2E). The significance of some
of these sequences including ISS-N1 and overlapping GC-rich
sequence has been described earlier (48, 52). In particular,
human-specific ISS-N1 and GC-rich motifs weaken the 5 ss of
SMN exon 7 (48, 52).
Depletion of TIA1 promotes SMN2 exon 7 skipping. To assess
the impact of reduced levels of TIA1 on SMN2 exon 7 splicing,
we used an RNA interference-based approach. Here, HeLa
cells were cotransfected with siRNAs of interest and the SMN2
minigene. Samples were collected at 24 h, 48 h, and 72 h
products from SMN2 (35). SMN1 and SMN2 spliced products with exon 7 included or skipped are indicated. The percentage of SMN2 exon 7
skipping was calculated from the total value of SMN2 exon-skipped and exon-included products. Control refers to untransfected cells. The results
of Western blotting are shown in the right panel. Nuclear and cytoplasmic fractions are marked. A total of 15 g of protein was used for nuclear
and cytoplasmic samples. Primary antibodies used for probing are indicated on the left. Bands corresponding to FLAG-tagged (*) and endogenous
(**) TIA1 are marked on the right. TATA binding protein (TBP) served as a nuclear marker, whereas GAPDH served as a cytoplasmic marker.
Cytoplasmic fraction from untransfected cells was used as a negative and positive control for nuclear and cytoplasmic markers, respectively.
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posttransfection, and the splicing patterns of both endogenous
and minigene-derived SMN2 pre-mRNAs were tested. The
level of TIA1 protein was examined by Western blotting 48 h
posttransfection. Considering that TIA1 displays functional re-
dundancy with TIAR, including the ability to promote SMN2
exon 7 inclusion (Fig. 1B), we also sought to test splicing of
SMN2 exon 7 when TIAR was knocked down. As a positive
control, we used siRNAs against hnRNP Q1 and Tra-2 that
have been previously shown to promote SMN2 exon 7 inclusion
(7, 23). In addition, siRNAs against all four proteins (TIA1,
TIAR, hnRNP Q1, and Tra-2) were simultaneously used for
transfection. A nonfunctional siRNA pool served as a negative
control. All siRNA experiments were successful in depleting
their respective proteins, as indicated by the results of Western
FIG. 2. Effect of TIA1 knockout on splicing of SMN exon 7. (A) Western blot showing levels of TIA1 and its homolog TIAR in wild-type and
in TIA1/ knockout mouse embryonic fibroblasts. Cellular proteins were fractionated, and 15 g of protein of the nuclear/cytoplasmic fractions
was used for SDS-PAGE. Primary antibodies used for probing are indicated on the left. GAPDH and histone 3 (H3) were used as markers for
cytoplasmic and nuclear fractions, respectively. (B) Splicing pattern of mouse endogenous Smn exon 7 in TIA1/ knockout mouse embryonic
fibroblasts. Total RNA was prepared from wild-type or TIA1/ knockout mouse embryonic fibroblasts, DNase treated and used for RT-PCR. One
microgram of total RNA was used per 20 l of reverse transcriptase reaction mixture. For the PCR step, mouse-specific primers annealing to exons
6 and 8 were employed. PCR amplification was done for 22 cycles; PCR products were ethanol precipitated and resolved on a native 5% PAGE
gel. (C) In vivo splicing patterns of SMN1 and SMN2 minigenes in mouse embryonic fibroblasts. Mouse embryonic fibroblasts (wild type or TIA1
knockout) were transfected with 1 g of SMN1 or SMN2 minigene and collected for total RNA preparation 24 h later. Spliced products were
analyzed by RT-PCR as described in the legend of Fig. 1B. (D) Comparison of introns 6 and 7 of human (SMN) and mouse (Smn) genes. Exons
are shown as colored boxes, and introns are shown as broken lines. Sizes of introns are given. 10C, a human intronic nucleotide involved in
long-distance interactions, is shown (53). (E) Alignment of the 5 end of human and mouse intron 7. Numbering starts from the beginning of the
intron. Nucleotides identical between human and mouse are highlighted in gray. Nonconserved mouse residues are shown in lowercase letters. The
10th intronic position is circled. ISS-N1, GC-rich sequence, and 10C are specific to humans (48, 52, 53).
940 SINGH ET AL. MOL. CELL. BIOL.
 o
n
 January 26, 2016 by IO
W
A STATE UNIVERSITY
http://m
cb.asm
.org/
D
ow
nloaded from
 
blotting (Fig. 3A). Depletion of TIA1 resulted in a noticeable
increase in SMN2 exon 7 skipping from transcripts derived
from the minigene (Fig. 3B). The effect was more pronounced
at 48 h posttransfection since we observed more than a 40%
increase in SMN2 exon 7 skipping (calculated from a base value
of the si-control sample). As expected, depletion of Tra2-,
TIAR, and hnRNP Q also promoted exon 7 skipping from
SMN2 minigene-derived transcripts. However, depletion of
TIA1 had the greatest negative impact on SMN2 exon 7 splic-
ing. Interestingly, the simultaneous depletion of all four splic-
ing proteins (TIA1, TIAR, hnRNP Q, and Tra2-) did not
produce a synergistic negative effect, suggesting that the above
factors do not interact among each other to induce SMN2 exon
7 inclusion (Fig. 3B). It is possible that simultaneous depletion
of these factors may have upregulated other proteins with
redundant splicing functions. It is also probable that reduced
levels of one or more factors may have downregulated negative
splicing factors.
As for the transcripts derived from endogenous SMN2, de-
pletion of TIA1 resulted in 20% increase in skipping of exon
7 (Fig. 3C, DdeI-digested bands). These results are consistent
with the results of increased skipping of SMN2 exon 7 in the
TIA1/ cells (Fig. 2C). We found that the effect of TIA1
depletion on endogenous SMN2 exon 7 splicing was weaker
than the effect on splicing of minigene-derived transcript. The
differential response between the SMN2 minigene and endog-
enous SMN2 could be in part due to differences in the up-
stream context including a large promoter sequence through
which additional factors may be recruited to the endogenous
pre-mRNA. Indeed, a recent report suggested that the pro-
FIG. 3. Effect of depletion of TIA1 and other stimulatory proteins on SMN exon 7 splicing. (A) Western blot showing the effect of the indicated
siRNAs on the level of corresponding proteins. HeLa cells were cotransfected with 1 g of the SMN2 minigene, and either 100 nM individual
siRNA or all siRNAs simultaneously (25 nM each); whole-cell lysates were prepared 48 h after transfection. Primary antibodies used for probing
are indicated on the left. (B) Time course of siRNA effect on splicing of SMN2 minigene-derived exon 7. Cotransfections were done as described
in panel A. Spliced products were analyzed by RT-PCR using minigene-specific primers, and total RNA was isolated from cells collected 24, 48,
and 72 h after transfection. (C) Time course of siRNA effect on splicing of endogenous SMN exon 7. Cotransfections were done as described in
panel A. Spliced products were analyzed by RT-PCR as described in panel B except that different primers, one located in exon 5 (N-23) and the
other in exon 8 (P25), were used. Following RT-PCR, DdeI digestion was performed to distinguish spliced products from SMN2 (35). The
percentage of SMN2 exon 7 skipping was calculated as in Fig. 1D.
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moter region has a role in regulation of SMN exon 7 splicing
(39). Overall, the results of TIA1 depletion support a stimu-
latory role of this protein in SMN2 exon 7 splicing.
TIA1 binding site is located downstream of ISS-N1. Pub-
lished reports suggest that TIA1 exerts its function in splicing
by directly interacting with a U-rich sequence immediately
downstream of the 5 ss of the affected exon. However, there
are no U-rich motifs immediately downstream of the 5 ss of
SMN exon 7. Furthermore, our earlier finding that sequestra-
tion of either the GC-rich motif or ISS-N1 fully restores SMN2
exon 7 inclusion ruled out the possibility that there is a stim-
ulatory motif within the first 24 residues of intron 7 (48, 52).
Therefore, we focused on intronic sequences downstream of
ISS-N1. We started by generating SMN2 mutant minigenes
with large intron 7 deletions and testing their in vivo splicing
patterns in the presence of overexpressed TIA1. Unless men-
tioned otherwise, these experiments were performed at an
optimized 1:3 ratio of minigene to 3XFLAG-tagged hTIA1
vector. As shown in Fig. 4A, the SMN2 mutant with a deletion
of residues 190 to 406 in intron 7 (I7190–406) that eliminated
most of the 3 half of intron 7 caused an improvement in exon
7 inclusion compared to that of the wild-type SMN2. This
mutant responded positively to the overexpression of TIA1,
suggesting that the binding site of TIA1 is not present in the
deleted region. In contrast, SMN2 mutant I730–100 almost
entirely lost the ability to include exon 7 with or without over-
expressed TIA1, suggesting that this region encompasses one
or more positive regulators (Fig. 4A). To clarify that the TIA1
binding site is distinct from the previously described element 2
located in this region (41), we created SMN2 constructs in
which either element 2 or an area upstream was deleted (Fig.
4A, mutants I756–82 and I729–60). While I756–82 re-
tained the ability to respond to TIA1, albeit with less efficiency,
I729–60 became completely refractory to the overexpression
of the protein (Fig. 4A). Thus, the region between ISS-N1 and
element 2 emerged as the binding site for TIA1. Of note,
more than 50% of the nucleotides in this region are U
residues (Fig. 4B).
When site-specific mutations (deletions or substitutions) are
used as an approach to find a potential binding site for a
splicing factor, there is a possibility that deletion or substitu-
tion within the wild-type sequence may abrogate a sequence/
structure motif or/and create a new motif. To confirm that
I729–60 indeed disrupted TIA1 binding, we performed an
antisense oligonucleotide (ASO) microwalk in which ASOs
blocking overlapping targets downstream of ISS-N1 were used.
Here, the SMN2 minigene was cotransfected with an ASO of
interest in the presence or absence of a TIA1 expression vec-
tor. A nonspecific ASO was used as a negative control. Con-
firming the stimulatory nature of the region, three out of four
ASOs increased SMN2 exon 7 skipping (Fig. 4B). A fourth
ASO (24Dn16) that blocked the longest non-U-rich tract did
not have any appreciable consequence on exon 7 splicing (Fig.
4B, lane 5). As shown in Fig. 4B, the overexpression of TIA1
promoted a dramatic increase in exon 7 inclusion only in the
presence of the control ASO, while in the presence of 14Dn16,
29Dn16, and 35Dn15 most of exon 7 skipping was retained.
Even the “ineffective” 24Dn16 noticeably decreased the posi-
tive effect of TIA1 (Fig. 4B). These results provided strong
corroborative evidence in support of the location of TIA1
biding site between ISS-N1 and element 2.
Using an ASO-based approach we next tested whether a
TIA1-associated intronic cis element was still required in the
absence of ISS-N1, a major inhibitory element responsible for
SMN2 exon 7 skipping. Here, we transfected an ASO of inter-
est with SMN2 mutant minigenes in which ISS-N1 was either
deleted or moved away from the 5 ss (48) (see Fig. S1 in the
supplemental material). Despite the loss of ISS-N1, the region
between ISS-N1 and element 2 retained its stimulatory effect.
This was most obvious in case of 29Dn16 that caused predom-
inant skipping of SMN2 exon 7 with or without overexpression
of TIA1 (see Fig. S1B). These results revealed that TIA1 is an
essential splicing factor for full restoration of SMN2 exon 7
inclusion. Consistently, 29Dn16 led to a significant increase in
exon 7 skipping from endogenous SMN2 in several cell lines
tested (see Fig. S1C and D).
URC1 and URC2 collaborate to promote TIA1-associated
inclusion of SMN2 exon 7 splicing. The sequence specificity of
RRM-containing proteins generally comes from direct inter-
actions of RRMs with a small stretch of nucleotides (11).
Based on our results (Fig. 4), U-rich sequences downstream of
ISS-N1 emerged as the likely sites for direct interactions with
TIA1. As shown in Fig. 5A, the region starting immediately
downstream of ISS-N1 and ending with element 2 contains
three of what we called U-rich clusters or URCs (delineated
based on the occurrence of U runs). To narrow down the
potential binding site of TIA1, we generated a series of SMN2
mutant minigenes with shorter (10 to 14 nucleotides) overlap-
ping deletions that covered the above-mentioned region (Fig.
5A) and tested their in vivo splicing patterns in the presence or
absence of overexpressed TIA1. URC1 contains UCUU, UU
NCUUU, and CUUUU motifs. Interestingly, the last two have
been shown to be significantly enriched downstream of the 5
ss of constitutive and alternative exons (3). URC2 contains two
UUU motifs separated by an AUGG stretch. As shown in Fig.
5, major deletions within URC1 or URC2 substantially re-
duced the ability of TIA1 to restore SMN2 exon 7 inclusion,
suggesting the additive effect of these motifs. In contrast, de-
letions between URC1 and URC2 did not affect the ability of
TIA1 to restore SMN2 exon 7 inclusion. These findings are
consistent with the results of the antisense microwalk (Fig.
4B) and suggest that URC1 and URC2 are the sites of direct
interaction with TIA1. One of our deletion mutations that
created a longer URC by bringing URC1 closer to URC2 fully
retained the stimulatory effect of TIA1 (Fig. 5, mutant I737-
48). On the other hand, deletion of 10 nucleotides (UUUAU
GGUUU) that eliminated both UUU motifs within URC2
substantially reduced the stimulatory effect of TIA1 (Fig. 5,
mutant I746-55). Consistently, replacement of two UUU mo-
tifs within URC2 with nonuridine nucleotides almost com-
pletely eliminated TIA1-associated stimulatory response (Fig.
5, mutant URC2S6A).
To corroborate the results of deletion mutations, we then
tested a large number of substitutions introduced in URC1/
URC2 using an unbiased approach of sequence randomization
at selected positions. Most of the substitutions reduced the
stimulatory effect of overexpressed TIA1 on SMN2 exon 7
splicing (Fig. 5; see also Fig. S2 and S3 in the supplemental
material). Interestingly, a 3-nucleotide substitution that re-
942 SINGH ET AL. MOL. CELL. BIOL.
 o
n
 January 26, 2016 by IO
W
A STATE UNIVERSITY
http://m
cb.asm
.org/
D
ow
nloaded from
 
placed UUU residues with CAC residues between the 53rd
and 55th position of intron 7 had a substantial negative effect
on SMN2 exon 7 splicing (Fig. 5B, lane 25). Also, this mutant
responded poorly to the overexpression of TIA1 (Fig. 5B,
lanes 25 and 26). Our results once again confirmed that
URC1 and URC2 are responsible for the TIA1-mediated
increase in SMN2 exon 7 inclusion. These results also under-
scored the significant finding that the TIA1-associated stimu-
latory function of U-rich motifs is exerted from beyond the
50th position of an intron.
URC1/URC2-linked stimulatory effect of TIA1 is portable.
To validate that the stimulatory effect of TIA1 on SMN2 exon
7 splicing in vivo is independent of sequences downstream of
URC2, we used a hybrid minigene Casp3SMN2 (53). In this
minigene, the alternatively spliced Casp3 exon 6 and its flank-
ing intronic sequences were replaced with SMN2 exon 7 and its
FIG. 4. Identification of intronic sequences responsible for TIA1-associated stimulatory effect on SMN2 exon 7 splicing. (A) Effect of deletions
in intron 7 on the ability of TIA1 to promote inclusion of SMN2 exon 7. Diagrammatic representation of deletions within intron 7 of the SMN2
minigene is given. Numbering of nucleotides starts from the first position of intron 7. Deletions are represented by dotted lines. Names of mutants
are given on the left. Numbers in the names represent positions of the first and the last deleted nucleotides. In vivo splicing patterns of the wild-type
SMN2 minigene and intron 7 deletion mutants in the absence and presence of overexpressed TIA1 are shown in the lower panel. HeLa cells grown
in 24-well plates were cotransfected with 0.04 g of a given minigene and 0.118 g of either empty vector or 3XFLAG-hTIA1. This amount of
3XFLAG-hTIA1 plasmid is similar to the lowest concentration used in the experiment shown in Fig. 1D downscaled to a 24-well plate. Results
were analyzed as described in the legend of Fig. 1B. (B) Splicing pattern of the SMN2 minigene cotransfected with different ASOs targeting
sequences between ISS-N1 and element 2. Diagrammatic representation of ASOs and their annealing positions are given. Numbering of
nucleotides starts from the first position of intron 7. ISS-N1 (gray) and element 2 (black) sequences are demarcated. ASOs are shown as horizontal
bars. The lower panel shows the in vivo splicing pattern of the SMN2 minigene in the presence of different ASOs with () or without ()
overexpressed TIA1. Experiments were performed with HeLa cells cotransfected with 0.04 g of minigene, a 100 nM concentration of a given ASO,
and 0.2 g of either an empty vector or 3XFLAG-hTIA1. Results were analyzed as described in the legend of Fig. 1B.
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flanking intronic sequences, including 116 nucleotides of up-
stream intron 6 and 99 nucleotides of the downstream intron 7
(Fig. 6A). This exchange created a context in which splice sites
of exons upstream and downstream of SMN2 exon 7 sub-
stantially differed from the wild-type SMN2. As shown in
Fig. 6B, splicing of Casp3SMN2 produced predominant skip-
ping of SMN2 exon 7, but the overexpression of TIA1 was
accompanied by an increase in inclusion of this exon. Gradual
deletion of element 2 had no apparent effect on the ability
of TIA1 to promote exon 7 inclusion (Fig. 6B, minigenes
Casp3HYB83–99, Casp3HYB65–99, and Casp3HYB56–
99). However, deletion of sequences that included URC1
and URC2 in the absence or presence of element 2 led to a
drastic decrease in the stimulatory response of overexpressed
TIA1 (Fig. 6B, Casp3HYB40–99, Casp3HYB25–99 and
Casp3HYB29–60). These results are in full agreement with
the results in the wild-type context in which deletion of se-
quences between ISS-N1 and element 2 led to a nearly total
loss of SMN2 exon 7 inclusion that could not be rescued by
overexpression of TIA1 (Fig. 5). Deletion of URC1 alone
(Casp3HYB29–41, the hybrid Casp3 minigene with deletion
of residues 29 to 41) in the heterologous context reduced the
ability of TIA1 to promote SMN2 exon 7 inclusion compared
to the wild-type context (Fig. 6C). Interestingly, ASO-medi-
FIG. 5. Role of URC1 and URC2 on the TIA1-associated stimulatory effect on SMN2 exon 7 splicing. (A) Diagrammatic representation of
mutations within intron 7 of the SMN2 minigene. Numbering of nucleotides starts from the first position of intron 7. Deletions are represented
by dotted lines. Site-specific mutations are highlighted in black. Names of mutants are given on the left. Numbers in the names of deletion mutants
represent positions of the first and the last deleted nucleotides. ISS-N1, element 2, and URCs are highlighted in red, green, and chartreuse yellow,
respectively. (B) In vivo splicing pattern of the SMN2 mutants shown in panel A. Cotransfection and splicing analysis were done similar to the
method described in the legend of Fig. 4A. The bar diagram shown in the bottom panel represents residual exon 7 skipping for different mutants
in the presence of 3XFLAG-hTIA1. Results in the bar diagram are expressed as per the following equation: 100 [(exon 7 skipped in the presence
of TIA1)/(exon 7 skipped in the absence of TIA1)]. Error bars based on standard deviation have been indicated. Standard deviation was
determined based on three independent experiments performed in duplicates.
944 SINGH ET AL. MOL. CELL. BIOL.
 o
n
 January 26, 2016 by IO
W
A STATE UNIVERSITY
http://m
cb.asm
.org/
D
ow
nloaded from
 
FIG. 6. Portability of TIA1-associated stimulatory response of URC1/URC2 in a heterologous context. (A) Diagrammatic representation of the
Casp3SMN2 hybrid minigene and its mutants. Casp3 and SMN2 sequences in the minigene are highlighted in dark and light red, respectively.
Numbering of nucleotides starts from the first position of SMN2 intron 7. ISS-N1, element 2, and URCs are highlighted in red, green, and yellow,
respectively. Deletions are represented by dotted lines. Numbers in the names of the hybrid minigenes represent positions of the first and the last
deleted nucleotides. ASO 35Dn15 is indicated by a blue horizontal bar, and its annealing position is shown. (B) In vivo splicing pattern of hybrid
minigenes shown in panel A in the presence of overexpressed TIA1. HeLa cells grown in 24-well plates were cotransfected with 0.04 g of a given
hybrid minigene and 0.36 g of either an empty vector or 3XFLAG-hTIA1. Splicing analysis was done similarly as described in the legend of Fig.
4A. The bar diagram shown in the bottom panel represents residual exon 7 skipping for different mutants in the presence of 3XFLAG-hTIA1.
Results in the bar diagram were expressed as described in the legend of Fig. 5B. Error bars based on standard deviation have been indicated. (C) In
vivo splicing patterns of Casp3SMN2 and Casp3HYB29–41 in the presence of TIA1 and a URC2-targeting ASO. HeLa cells grown in 24-well
plates were cotransfected with 0.04 g of minigene, a 100 nM concentration of a given ASO, and 0.36 g of either an empty vector or
3XFLAG-hTIA1. Results were analyzed as described in the legend of Fig. 1B. Error bars were generated from standard deviations similar to the
method described in the legend of Fig. 5B.
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ated blocking of URC2 in the context of deleted URC1 led to
a nearly complete loss of SMN2 exon 7 inclusion even in the
presence of overexpressed TIA1 (Fig. 6C, lanes 7 and 8). With
selective blocking of URC2 only some of the stimulatory effect
of TIA1 was retained (Fig. 6C, lanes 3 and 4). These results
once again confirmed the additive effect of URC1 and URC2
on the TIA1-associated stimulatory response on SMN2 exon 7
inclusion. Of note, to observe the stimulatory effect of TIA1 in
a heterologous context comparable to the one produced in
wild-type (SMN2 minigene) context, we used three times as
much of the TIA1 expression vector. While our results con-
firmed the portability of the TIA1-associated stimulatory
effect of intronic U-rich sequences away from the 5 ss, they
also indicated the complexity of the exon definition process
in which context-specific determinants including sequences
downstream of URC2 would have influenced the degree of
the stimulatory effect of TIA1.
In vitro binding supports affinity of TIA1 to URC1 and
URC2. To appreciate the specificity of the direct interaction
between TIA1 and sequences downstream of ISS-N1, we per-
formed in vitro binding employing purified TIA1 and RNA
substrates with URC1 and URC2 motifs. The recombinant
TIA1 was purified using the Impact system, which allows pro-
duction of tag-free proteins in a single chromatographic step
(10) (see Fig. S4 in the supplemental material). The wild-
type SMN2 substrate used contained the first 86 nucleotides
of intron 7, including the 5 ss, ISS-N1, URC1, URC2, and
URC3. Mutant transcripts carried deletions/substitutions iden-
tical to the ones in the SMN2 mutant minigenes used for the in
vivo splicing assay (Fig. 5 and 7). The in vitro binding affinity of
TIA1 to various RNA substrates was determined using the
nitrocellulose-filter binding assay as described earlier (55). Our
experimental design allowed comparison of binding strengths
of two substrates in a single reaction. We performed two sets of
FIG. 7. In vitro binding of purified TIA1 with RNA substrates harboring URC1 and/or URC2. (A) Diagrammatic representation of RNA
transcripts used for in vitro binding. Deletions in transcripts are represented by dotted lines. Site-specific mutations are highlighted in black. Names
of transcripts are given on the left, and their lengths are shown on the right. URC1, URC2, and URC3 are highlighted in gray. Sequence 1-1 (seq
1-1) is a high-affinity ligand reported earlier (16). (B) Relative affinity of TIA1 for different RNA substrates described in panel A. Employing a
nitrocellulose filter assay, binding strengths of different RNA substrates were compared with either wild-type sequence (upper panel) or sequence
1-1 (lower panel). Results were expressed by computing the fraction of input RNA substrate bound to the membrane against a common competing
RNA (55). The bound molar ratio of each mutant was compared with the wild-type construct, the value for which was assigned as 1.
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experiments. In the first set of experiments, all mutant tran-
scripts were smaller than the wild-type transcript (Fig. 7B,
lanes 1 to 20). Loadings were adjusted to maintain the wild-
type construct at similar intensities in both input and bound
fractions (Fig. 7B, top bands in lanes 1 to 20). Such an arrange-
ment allowed easy comparison between input and bound frac-
tions. In the second set of experiment, all mutant transcripts
were the same size as the wild-type transcript (Fig. 7B, lanes 21
to 36). The binding strength of the mutants was compared with
sequence 1-1, a 71-nucleotide-long RNA transcript that was
shown to have high affinity for TIA1 (16). Here, loadings were
adjusted to maintain sequence 1-1 at similar intensities in both
input and bound fractions (Fig. 7B, bottom bands in lanes 21 to
36). Again, such an arrangement made a comparison between
input and bound fractions easy.
In keeping with the preference of TIA1 for U-rich motifs,
all deletions encompassing U residues had an adverse effect
on TIA1 binding (Fig. 7). Among the 10 overlapping dele-
tions tested, the individual or combined deletions of URC1
or URC2 were the most deleterious for TIA1 binding. The
combined deletion of URC1 and URC2 led to a more than
6-fold decrease in TIA1 binding (Fig. 7, mutant I729-60),
while the deletion encompassing URC3 that harbors the long-
est U-rich tract led to only a 2-fold decrease in TIA1 binding
(Fig. 7, mutant I770-82). Interestingly, the deletion of URC2,
which brings two U-rich sequences, URC1 and URC3, closer
to each other, had a negative effect on TIA1 binding. These
results indicate that the relative arrangement of URC1 and
URC2 within wild-type context creates a high-affinity binding
site for TIA1. Validating the results of deletion mutations, up
to a 4-fold decrease in binding was observed for RNA tran-
scripts bearing substitutions in URC1 or URC2 (Fig. 7). This
observation indicates that the decreased binding of TIA1 to
transcripts with deletions was due not merely to the reduction
in their sizes. Overall, our results are consistent with a se-
quence-specific effect of TIA1-associated stimulation of SMN2
exon 7 inclusion in vivo (Fig. 5). Interestingly, we observed that
TIA1 showed higher affinity for wild-type SMN2 RNA than
sequence 1-1. This observation is significant and provides ad-
ditional support in favor of a tight interaction between TIA1
and SMN2 sequences downstream of ISS-N1. Notably, one of
the mutants, URC1S2A, also showed high TIA1 binding de-
spite the fact that this mutation in the SMN2 minigene reduced
the ability of overexpressed TIA1 to promote exon 7 inclusion.
A discrepancy of this nature is not totally unexpected and
could be attributed to a variety of factors, including creation of
a binding site for a negative regulator of splicing. In general,
the results of in vitro binding provide very strong evidence in
support of a direct and sequence-specific interaction between
TIA1 and the sequences downstream of ISS-N1.
Role of different domains in TIA1-mediated splicing regu-
lation. There has been limited study on the role of individual
TIA1 domains on splicing regulation in vivo. Due to the
changed context of the TIA1 interaction away from the 5 ss,
we next wished to determine what portion of TIA1 governs its
ability to affect SMN2 exon 7 splicing. For this, we generated
3XFLAG expression vectors of individual TIA1 domains as
well as different combinations of two and three domains (Fig.
8A). These expression vectors were cotransfected with the
SMN2 minigene, and total RNA and cellular lysates for West-
ern blotting were prepared at 24 h posttransfection. The results
of Western blotting confirmed that all TIA1 variants were
expressed to comparable levels, except RRM2 and Q, whose
expression levels were very low (Fig. 8C). These results are in
line with the varied stability levels of different domains. How-
ever, our meticulous design of domain combinations was able
to probe the significance of every single domain in the absence
of one or more domains. As shown in Fig. 8B, individual RRM
domains had no effect on exon 7 splicing. It is likely that the
inability of individual RRM domains to stimulate exon 7 splic-
ing could be due to poor nuclear import. Indeed, it has been
shown that RRM2 is involved in nuclear import while RRM3
is important for nuclear export of the protein (68). However,
immunocytochemistry with our representative RRM1 construct
showed uniform distribution between nucleus and cytoplasm,
suggesting that the loss of the stimulatory response of RRM1
is not due to the lack of its nuclear import (see Fig. S5 in the
supplemental material).
The Q domain, despite its poor expression, caused a small
but reproducible increase in exon 7 inclusion. This could be
due to the inherent ability of the Q domain to interact with
other proteins including endogenous TIA1/TIAR that may
have been recruited, albeit poorly, at URC1/URC2. When the
Q domain was added to any of the RRMs, the ability of these
constructs to enhance exon 7 inclusion increased significantly,
with RRM2Q being the most and RRM3Q being the least
“splicing”-active variant (Fig. 8B). Remarkably, even with low
expression, RRM2Q was as effective as full-length TIA1 in
promoting exon 7 inclusion. Other constructs in which the Q
domain was absent produced very little, if any, effect on exon
7 splicing, except for RRM1RRM2, which caused a small
improvement in exon 7 inclusion (Fig. 8B, lanes 13 to 16).
Constructs in which a single RRM domain was deleted were
still able to promote exon 7 inclusion in the following order
from most to least active: RRM3, RRM2, and RRM1
(Fig. 8B, lanes 10 to 12). Taken together, our results suggest
that the Q domain is indispensable for the ability of TIA1 to
affect SMN2 exon 7 splicing in vivo.
Distribution of splicing-stimulatory signals within the Q
domain of TIA1. The TIA1 Q domain contains 21 glutamine
residues unevenly distributed within a span of 97 amino acids
located toward the C terminus of the protein. To evaluate the
role of subsequences within the Q domain, we examined the
effect of progressive deletions from the C terminus of TIA1 on
SMN2 exon 7 splicing. As shown in Fig. 9, deletion of the last
57 amino acids of TIA1 containing 10 glutamine residues had
no effect on splicing (TIA1Q3). However, further deletion of
20 additional amino acids led to a drastic decrease in the
stimulatory effect of TIA1 (Fig. 9B, compare splicing patterns
in the presence of TIA1Q3 and TIA1Q4). The stimulatory
effect of TIA1 was almost entirely lost when the whole Q
domain was deleted (Fig. 9, TIA1Q5b). To eliminate the
possibility that the lack of the Q domain negatively affected
folding and therefore splicing activity of the TIA1, we gener-
ated fusion constructs in which 30 unrelated amino acids
were added to the C terminus of RRM123 (Fig. 8), gen-
erating the fusion 1a and fusion 2b constructs (Fig. 9A). Note
that overexpression of RRM123 did not affect SMN2 exon
7 splicing (Fig. 8B). Although the lengths of fusion 1a and 2b
are comparable to the length of the relatively active TIA1Q3
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construct, neither fusion 1a nor fusion 2b showed appreciable
improvement in promoting exon 7 inclusion (Fig. 9). Interest-
ingly, fusion 2b had about twice as many glutamine residues as
the wild-type subsequence and yet was unable to recover the
stimulatory response. These results suggest that other residues
in combination with glutamines may be contributing to the
stimulatory effect of the Q domain on splicing.
Nuclear import of TIA1 is essential for its ability to affect
pre-mRNA splicing. One in vivo study suggested that the first
50 amino acids of the Q domain of TIA1 are required for
nuclear accumulation of TIA1 (68). On the other hand, an
earlier in vitro study had implicated the Q domain in the
recruitment of U1 snRNP at the 5 ss (18). Our finding that the
first half of the Q domain retains full stimulatory effect in vivo
FIG. 8. Effect of different domains of TIA1 on SMN2 exon 7 splicing. (A) Diagrammatic representation of the structure of full-length TIA1
and its derivative constructs. RRMs and the Q-rich domain are indicated. Numbers represent amino acid positions. Numbers in the full-length
TIA1 were assigned based on Gilks et al. and Tian et al. (20, 57). (B) In vivo splicing pattern of the SMN2 minigene in the presence of different
TIA1 variants shown in panel A. All expressed TIA1 variants carried 3XFLAG tags at their N termini. HeLa cells were cotransfected with 0.04
g of SMN2 and either an empty vector or a TIA1 variant of interest. Amounts of expression vectors were adjusted to produce comparable levels
of protein expression (see panel C) and varied from 0.4 g to 1.96 g. The total amount of DNA used per transfection was maintained constant
by adding an empty vector when needed. Cells were collected 24 h after transfection. Results were analyzed as described in the legend of Fig. 1B.
(C) Western blot confirming expression levels of TIA1 variants shown in panel A. Twenty micrograms of total protein was used for each sample.
Equal protein loading was confirmed by reprobing the blot for 	-tubulin. Primary antibodies used for probing are indicated on the left.
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is consistent with both observations. We next examined the
impact of subsequences located in the second half of the Q
domain. For this, we generated a TIA1 mutant in which the
N-terminal portion of the Q domain from amino acid 294 to
amino acid 343 was deleted (Fig. 9A, TIA1-3Q). Interestingly,
this variant regained some stimulatory response on splicing
compared to the TIA1Q5b construct in which the entire 97
residues of the Q domain were deleted (Fig. 9B). These results
reveal that the second half of the Q domain, despite its low Q
content, retains some of the stimulatory function.
TIA1 counteracts the inhibitory effect of PTB. The multi-
functional PTB (also referred to as hnRNP I) is a widely
expressed protein that binds preferentially to polypyrimidine-
rich sequences (2, 45, 46, 54). PTB contains four RRMs and an
N-terminal nuclear localization signal. Nuclear magnetic
resonance (NMR) structures of PTB RRMs show variations
in sequence preferences (2). In addition to interaction with
pyrimidine-rich sequences, three RRMs (RRM2, RRM3,
and RRM4) of PTB are capable of engaging in protein-protein
interactions (2). PTB is known to facilitate exon skipping by
FIG. 9. Effect of Q-rich domain shortening on SMN2 exon 7 splicing. (A) Diagrammatic representation of deletions/substitutions in the Q-rich
domain of TIA1. RRMs and the Q-rich domain are indicated. Numbers represent amino acid positions. For the purposes of comparison, amino
acid sequences of different deleted variants of the Q domain are given in the lower panel. Red letters represent C-terminal residues of RRM3.
Black and blue letters denote the first 54 residues of the Q domain and the last 43 residues of TIA1, respectively. Green letters represent unrelated
amino acid sequences added to the C terminus of a truncated TIA1 lacking the last 87 residues. Glutamine residues of TIA1 are shown in white
letters and highlighted in black. (B) In vivo splicing pattern of the SMN2 minigene in the presence of TIA1 proteins shown in panel A. All expressed
TIA1 variants carried 3XFLAG tags at their N termini. HeLa cells were cotransfected with 0.04 g of SMN2 and either an empty vector or the
TIA1 protein expression vector of interest. The amounts of TIA1 expression vectors were adjusted to produce comparable levels of protein expression
(Western blot panel) and varied from 0.4g to 0.96g. The total amount of DNA used per transfection was maintained constant by the addition of empty
vector when needed. Cells were collected for analysis 24 h after transfection as described in the legend of Fig. 8B and C.
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preventing recruitment of U2AF at the branch point, which is
located within the polypyrimidine tract immediately upstream
of an exon (54). Other skipping mechanisms take advantage of
multiple interactions at different sites within pre-mRNA. Such
interactions either loop out the exon or create a zone of si-
lencing (30, 60). Recently, PTB has been found to bind to
element 1, a silencer within intron 6 of SMN2 (4). However,
the mechanism by which PTB affects SMN exon 7 splicing
remains unknown. It is likely that SMN2 exon 7 splicing is
regulated by a combinatorial control in which the inhibitory
effect of PTB is offset, at least in part, by the stimulatory effect
of TIA1. To explore such a possibility, we set out to compare
the splicing patterns of the SMN2 minigene in HeLa cells
overexpressing PTB and/or 3XFLAG-hTIA1. We began our
experiments with optimization of PTB expression. Moderate
expression of myc-tagged PTB from 0.30 g of PTB expression
vector produced a noticeable increase in SMN2 exon 7 skip-
ping (Fig. 10A and C). Of note, a further increase in the
amount of this vector used for transfection led to a substantial
drop in the levels of SMN transcripts (data not shown). This
could be due to an indirect effect owing to alternation of other
cellular processes (46). To check the stimulatory response of
TIA1, we employed various concentrations of the TIA1 expres-
sion vector starting from 0.36 g. Expression levels of both
PTB and TIA1 were confirmed by Western blotting (Fig. 10C).
Our lowest TIA1 expression was able to fully counteract the
inhibitory effect of PTB while the highest TIA1 expression not
only nullified the inhibitory effect of PTB but also substantially
restored exon 7 inclusion in transcripts derived from the SMN2
minigene (Fig. 10A). We then compared the splicing pattern of
endogenous SMN exon 7 in the above samples employing a
primer combination that does not amplify minigene tran-
scripts. PTB caused increased skipping from 43% to 54% (Fig.
10B). A high concentration of TIA1 was able to counteract the
inhibitory effect of PTB and fully restored SMN2 exon 7 inclu-
sion to the level observed in untransfected cells (Fig. 10B).
Interestingly, overexpressed PTB had a mild inhibitory effect on
endogenous SMN1 exon 7 splicing. Here again, a high concen-
tration of TIA1 was able to counteract this effect (Fig. 10B).
To test whether PTB-associated skipping of SMN2 exon 7 is
executed through URC1 and URC2, polypyrimidine-rich se-
quences responsible for interaction with TIA1, we took advan-
tage of some of our previously described mutants. We com-
pared the splicing patterns of these mutants with or without
overexpressed PTB. Deletion of URC1 (mutant I729–40) or
URC2 (mutant I746–55) or sequences between URC1 and
URC2 (mutant I737–48) did not affect the ability of PTB to
promote SMN2 exon 7 skipping (Fig. 10D). These results sug-
gest that the TIA1 binding site within intron 7 does not overlap
with the motif responsible for PTB interaction. Interestingly,
FIG. 10. (A) In vivo splicing pattern of the SMN2 minigene in the
presence of overexpressed PTB1 and TIA1. HeLa cells grown in six-
well plates were cotransfected with 0.04 g of SMN2 (lanes 1 to 8), 0.3
g of myc-PTB expression vector (lanes 2 to 5), and various amounts
of 3XFLAG-hTIA1 (0. 36 g in lanes 3 and 6; 0. 73 g in lanes 4 and
7; and 1.46 g in lanes 5 and 8). Lane 9 served as an untransfected
control. The total amount of DNA used per transfection was main-
tained constant by the addition of empty vector when needed. Cells
were collected 24 h after transfection. Results were analyzed as de-
scribed in the legend of Fig. 1B. (B) Effect of overexpressed PTB and
TIA1 on splicing of endogenous SMN exon 7. Cotransfections were
done as described in panel A. Spliced products were analyzed by
RT-PCR as described in panel A, except that different primers, one
located in exon 6 (N-24) and the other in the portion of exon 8 that is
absent in the minigene (P26), were used. Following RT-PCR, DdeI
digestion was performed to distinguish spliced products from SMN2
(35). The percentage of SMN2 exon 7 skipping was calculated as
described in the legend of Fig. 1D. (C) Western blot showing the levels
of endogenous and recombinant myc-tagged PTB as well as endoge-
nous and recombinant FLAG-tagged TIA1. Twenty micrograms of
total protein was used for each sample. Equal protein loading was
confirmed by reprobing the blot for -actin. Primary antibodies used
for probing are indicated on the left. Bands corresponding to FLAG-
tagged (*) and endogenous (**) TIA1 are marked on the right. (D)
Effect of URC1 and URC2 deletions on the ability of PTB to promote
SMN2 exon 7 skipping. HeLa cells grown in 24-well plates were co-
transfected with 0.04 g of a given minigene and 0.30 g of either
empty vector or myc-PTB. Mutants are described the legend of Fig.
5A. Total RNA was isolated 24 h posttransfection. Results were ana-
lyzed as described in the legend of Fig. 1B
950 SINGH ET AL. MOL. CELL. BIOL.
 o
n
 January 26, 2016 by IO
W
A STATE UNIVERSITY
http://m
cb.asm
.org/
D
ow
nloaded from
 
these findings are consistent with the absence of a UYUYU
subsequence within URC1 or URC2. This subsequence was
recently identified as the top consensus motif for a PTB-RNA
interaction in a genome-wide analysis in vivo (64). Our results
support the role of TIA1 in counteracting the negative impact
of PTB on SMN exon 7 splicing.
DISCUSSION
Recent reports reveal critical roles for TIA1 and TIAR in
genome-wide positive regulation of pre-mRNA splicing
through specific interactions involving U-rich intronic motifs
adjacent to the 5 ss of exons (3, 19). The close proximity of
intronic U-rich sequences to the 5 ss allows TIA1 to facilitate
5 ss recognition by recruitment of U1 snRNP through direct
interactions (9, 15, 18, 32). Such a mechanism may exclude a
role for TIA1 in different contexts in which U-rich intronic
motifs are separated from the 5 ss by intervening negative
intronic cis elements. Moreover, it is not known if the stimu-
latory role of TIA1 is at all applicable to contexts in which
U-rich intronic motifs are located more than 30 nucleotides
away from the 5 ss. To explore the role of TIA1 in such a
context, we took advantage of SMN2 exon 7, skipping of which
is associated with SMA, a leading neurodegenerative disease.
The intronic sequences immediately downstream of the 5 ss of
exon 7 are marked by the absence of U-rich motifs character-
istic of TIA1 binding sites. In addition, the first 24 residues of
intron 7 harbor overlapping inhibitory cis elements (24, 48, 52,
53) (Fig. 11). Here, we report that TIA1 plays a prominent
stimulatory role in SMN2 exon 7 splicing through novel in-
tronic motifs located away from the 5 ss.
A significant effect of TIA1 on SMN2 exon 7 splicing regu-
lation emerged from a series of complementary experiments
that we performed in vivo. First, overexpression of recombi-
nant TIA1 or its closely related analog, TIAR, led to a sub-
stantial increase in exon 7 inclusion in transcripts derived from
the SMN2 minigene. A stimulatory effect of TIA1 was also
observed on exon 7 splicing from endogenous SMN2. Sup-
porting the result of TIA1 overexpression, SMN minigenes
transfected in a TIA1 knockout mouse cell line (TIA1/
cells) showed increased skipping of exon 7. The negative
consequence of the absence of TIA1 was specific to human
SMN as splicing of mouse Smn exon 7 appeared unaffected in
TIA1/ cells. Further validating the positive role of TIA1 and
TIAR on SMN2 exon 7 splicing, depletion of these factors
using an siRNA-based approach led to an increase in SMN2
exon 7 skipping.
To determine the role of a specific sequence(s) responsible
for a TIA1-associated stimulatory effect on SMN2 exon 7 splic-
ing, we adopted an open-ended approach in which we first
scanned the entire intron 7 through large deletions. With our
largest deletion (I7190–406), which eliminated numerous
URCs, including the longest U-rich motif comprised of eight U
residues in the 3-half of intron 7, the stimulatory effect of
TIA1 was fully retained. These results ruled out the possibility
that the TIA1 binding site is located in the 3 half of intron 7.
Thus, we focused on sequences in the first half of intron 7.
Overlapping deletions in this region revealed URC1 (UCUU
ACUUUUGU) and URC2 (UUUAUGGUUUGU) as possi-
ble sites of TIA1 interaction. URC1 and URC2 fall within 29th
and 57th positions of intron 7. Of note, simultaneous deletion
of URC1 and URC2 led to a complete loss of the TIA1-
associated stimulatory effect despite the fact that this deletion
brought URC3 (UGUUUUUGAACAUUUA) closer to the 5
ss. Complementing the results of deletion mutations, ASOs
blocking URC1 and URC2 led to increased SMN2 exon 7
skipping, even in the presence of overexpressed TIA1. The
results of ASO-based experiments were significant in ruling out
FIG. 11. Model of TIA1-mediated splicing regulation of SMN2 exon 7 splicing. The 5 portion of SMN intron 7 sequence containing various
splicing cis elements is shown. Numbering of nucleotides starts from the first position of intron 7. Roles of intronic cis elements ISS-N1, GC-rich,
element 2, and hnRNP A1 and PTB motifs have been described previously (4, 24, 41, 48, 52). Plus and minus signs indicate that a given splicing
factor promotes exon 7 inclusion and skipping, respectively. The nature of the stimulatory factor(s) (represented by “?”) interacting with element
2 is not known. Binding of TIA1 to URC1/URC2 brings a change in the context leading to recruitment of U1 snRNP at the 5 ss of exon 7. Also,
a TIA1-associated change in the context creates an unfavorable condition for the recruitment of negative splicing factors including hnRNP
A1 and PTB.
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the possibility of an indirect effect of inhibitory elements that
may have been inadvertently created by deletion mutations.
Further supporting the URC1/URC2-dependent stimulatory
role of TIA1, overexpression of TIA1 led to an increase in
exon inclusion in a heterologous context. Portability of URC1/
URC2 in a heterologous context underscores that TIA1/TIAR
may have an expanded role in splicing regulation through
URC1/URC2-like motifs away from the 5 ss.
To accurately define the TIA1 binding site, we used small
overlapping deletions. Several of these short deletions that either
fully or partially eliminated URC1 and/or URC2 reduced the
stimulatory effect of TIA1. These results imply roles for both
URC1 and URC2 in TIA1 binding. Complementing the results
of deletion mutations, substitutions within URC1 and URC2
also led to a decrease in/loss of the stimulatory effect of TIA1.
To confirm that in vivo splicing results of SMN2 minigenes
containing deletion and substitution mutations are in concert
with the loss of a direct interaction of TIA1 with URC1 and
URC2, we performed in vitro binding using purified TIA1 and
transcripts harboring identical mutations. The results of in vitro
binding fully supported a direct interaction of TIA1 with
URC1 and URC2. Consistently, substitutions within URC1 or
URC2 led to a reduction in affinity of TIA1 for RNA. Results
of in vitro binding also revealed that the interaction between
URC1/URC2 and TIA1 is tighter than the interaction of TIA1
with a high-affinity TIA1 binder isolated using in vitro selection
(Fig. 7). These results underscore that very low levels of
TIA1 in the nucleus should be able to modulate SMN2 exon
7 splicing.
Having determined the sequence-specific effect of TIA1 in a
novel context, we next examined the impact of individual TIA1
domains on SMN2 exon 7 splicing. Our results revealed the
essential role of the Q domain and confirmed that any RRM in
combination with the Q domain is necessary and sufficient to
stimulate SMN2 exon 7 splicing in vivo. This is not totally
unexpected since the RRMs of TIA1 share a high degree of
homology (57). Of note, a positive effect of a given TIA1
domain combination on pre-mRNA splicing in vivo is de-
pendent upon several limiting events, including a relatively
moderate expression, an appreciable level of nuclear im-
port, a reasonable affinity for the target, and the ability of this
domain combination to favorably interact with components of
spliceosome. Our finding that any RRM in combination with
the Q domain is able to stimulate SMN2 exon 7 splicing is
distinct from an in vitro study showing a specific requirement
for RRM1 in addition to the Q domain for the formation of a
tight interaction with U1 snRNP (18). The discrepancy be-
tween in vivo and in vitro results could be due to several factors,
including a change in the context of the 5 ss and coupling of
pre-mRNA splicing with transcription and polyadenylation in
vivo. A previous localization study had suggested a require-
ment for RRM2 and RRM3 in nuclear import and export,
respectively (68). However, since the study did not employ a
nuclear function in a sufficiently sensitive assay, the significance of
reduced nuclear import or export of a particular domain combi-
nation could not be evaluated. Our finding that the lack of
RRM2 has no adverse effect on SMN2 exon 7 splicing suggests
that RRM2 might be dispensable for nuclear import. Our
results argue that even a suboptimal level of nuclear import of
a critical splicing factor may have a substantial impact on
pre-mRNA splicing. In agreement with the results of different
domain combinations of TIA1, overexpression of TIA15 and
TIAR3 increased SMN2 exon 7 inclusion. These two proteins
are the major spliced variants of TIA1 and TIAR, respectively.
Based on our findings, we believe that even shorter and less
frequent spliced variants of TIA1 and TIAR would be able to
stimulate SMN2 exon 7 inclusion.
The essential role of the Q domain in SMN2 exon 7 splicing
prompted us to examine this domain in further detail. Unlike
the characteristic two RNP motifs within each RRM, the Q
domain does not contain a signature motif. Twenty-one glu-
tamine residues are randomly distributed within the Q domain.
With a deletion of the last half of the Q domain, most of the
splicing activity was retained, and some splicing activity was
retained with deletion of the first half of the Q domain. These
results suggest a cumulative effect in which a large number of
glutamine residues in the first half of the Q domain contrib-
uted toward the maximum activity. Consistently, the first 19
amino acids of the Q domain contain the highest density of
glutamine residues (32%) as well as the longest Q-rich motif
(QQQNQ), and this region was able to retain about one-third
of the total activity. These results, however, do not rule out the
possibility that amino acids other than glutamine residues in
the Q domain might play a supportive role in the splicing-
associated function of TIA1.
Our results support the bipartite nature of an interaction in
which TIA1 contacts two motifs (URC1 and URC2) within a
span of 29 nucleotides between the 29th and 57th positions of
intron 7. Such an interaction is consistent with the structural
studies in which the interface between RNA and an interacting
RRM domain is generally occupied by less than seven nucle-
otides (11). In the case of TIA1, the bipartite nature of inter-
action is possible through two RRMs of either the same or
different TIA1 molecules. Our finding that a single RRM in
combination with the Q domain is able to stimulate exon 7
inclusion suggests that URC1/URC2 is bound by a TIA1 dimer.
In addition, the high affinity of TIA1 to URC1/URC2 fits well
with the dimeric mode of interactions in which protein binding
to RNA is stabilized by protein-protein interactions and vice
versa.
Different mechanisms may account for the stimulation of
SMN2 exon 7 inclusion by TIA1. The most plausible among
those is the “prevention of negative recruitment.” According to
this model, TIA1 interaction with URC1/URC2 prevents re-
cruitment of negative factors, including hnRNP A1, upstream
of the TIA1 binding site (Fig. 11). This, in turn, would lead to
enhanced recruitment of U1 snRNP due to a now accessible 5
ss. This hypothesis is consistent with complementary findings in
which ASO-mediated blocking of a GC-rich motif or ISS-N1
promotes SMN2 exon 7 inclusion (24, 48, 52). In addition, our
recent report revealed a long-distance negative interaction in-
volving the 10th intronic position (53). Binding of TIA1 to
URC1/URC2 has a potential to prevent/abrogate this negative
interaction through hindering and/or sterically impacting the
accessibility of the 10th intronic position. The hypothesis of the
prevention of negative recruitment does not exclude another
possibility, i.e., that URC1/URC2-bound TIA1 directly recruits
U1 snRNP through looping out sequences between the 5 ss
and the TIA1 binding site. This hypothesis is consistent with
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the ability of RRMs and the Q domain to participate in pro-
tein-protein interactions (11).
Notable finding that TIA1 is able to counteract the inhibi-
tory effect of PTB suggests additional mechanisms in which
recruitment of TIA1 to URC1/URC2 brings dramatic changes
in the context of pre-mRNA. PTB promotes exon skipping
through different mechanisms (2). The most common among
them is the looping out of the skipped exon through binding to
flanking intronic sequences (30). A recent genome-wide anal-
ysis revealed subsequence UYUYU as the top scored consen-
sus motif for PTB-RNA interactions in vivo (64). Intronic se-
quences flanking SMN exon 7 are replete with such sequences.
Also, PTB has been shown to interact with element 1, which is
located within intron 6 of SMN (4). Element 1 harbors subse-
quence UUUUU as one of the top-scored PTB binding motifs.
Consistent with the absence of a UYUYU motif, our func-
tional study ruled out the presence of a PTB binding site within
URC1/URC2, which is the site of interaction with TIA1. How-
ever, there are additional UYUYU motifs downstream of
URC1/URC2. Interaction of PTB with element 1 within SMN
intron 6 and possible interaction within intron 7 may support
the looping-out mechanism. Another mechanism of PTB-asso-
ciated splicing regulation supports the formation of a zone of
silencing around a skipped exon (60). In addition to PTB, other
inhibitory factors such as hnRNP A1 and Sam68 have been
implicated in promotion of SMN2 exon 7 skipping. It is possi-
ble that PTB forms a zone of silencing around SMN2 exon 7
through interactions involving additional negative factors in-
cluding, but not limited to, hnRNP A1 and Sam68. Our results
suggest that the TIA1-induced contextual change within SMN
pre-mRNA is sufficient to prevent the inhibitory effect of PTB
on SMN exon 7 splicing.
SMN is a multifunctional protein with more than 20 reported
interacting partners. Through regulation of snRNP biogenesis
in the nucleus, SMN controls the rate of pre-mRNA splicing.
Consistently, depletion of SMN leads to genome-wide pertur-
bations of pre-mRNA splicing (70). SMN is a component of
stress granules, a dynamic cytoplasmic structure, formation of
which requires TIA1 and hnRNP A1 (22, 25). hnRNP A1 is a
negative regulator of SMN2 exon 7 splicing. Two out of four
putative hnRNP A1 binding sites are located immediately
upstream of the TIA1 binding site within intron 7. Our discov-
ery of TIA1 as a regulator of SMN exon 7 splicing provides a
unique precedence in which two splicing factors (TIA1 and
hnRNP A1) that cooperate in response to cellular stress play
opposing roles in regulation of SMN2 exon 7 splicing through
adjacent intronic motifs located in the vicinity of the 5 ss. Thus
far, studies on TIA1-assisted pre-mRNA splicing regulation
have focused on U-rich motifs close to the 5 ss. The finding
that TIA1 could modulate exon 7 inclusion through U-rich
intronic motifs separated from the 5 ss by negative cis ele-
ments brings new insight into our understanding of pre-mRNA
splicing of a critical exon associated with SMA, a leading ge-
netic disease of children and infants. Reduced levels of SMN in
SMA primarily affect motor neurons that generally maintain
high levels of SMN. It is also known that TIA1, TIAR, and
PTB are abundantly expressed in the brain (5, 14). Hence,
regulation SMN2 exon 7 splicing by TIA1/TIAR has signifi-
cance in maintaining the high levels of SMN in the brain.
Skipping of SMN2 exon 7 has been also associated with con-
ditions of oxidative stress that causes Parkinson’s and Alzhei-
mer’s disease (37). Thus, our findings provide a broader role of
TIA1/TIAR in alleviating the severity of a large number of
diseases associated with low levels of SMN.
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